Pilocarpine Ophthalmic Topical Cream, Dose 1 + Pilocarpine Ophthalmic Topical Cream, Dose 2 + Pilocarpine Ophthalmic Topical Cream, Dose 3 + Placebo Ophthalmic Topical Cream
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia
Trial Timeline
Jan 3, 2022 → Sep 6, 2022
NCT ID
NCT05124275About Pilocarpine Ophthalmic Topical Cream, Dose 1 + Pilocarpine Ophthalmic Topical Cream, Dose 2 + Pilocarpine Ophthalmic Topical Cream, Dose 3 + Placebo Ophthalmic Topical Cream
Pilocarpine Ophthalmic Topical Cream, Dose 1 + Pilocarpine Ophthalmic Topical Cream, Dose 2 + Pilocarpine Ophthalmic Topical Cream, Dose 3 + Placebo Ophthalmic Topical Cream is a phase 2 stage product being developed by Glaukos for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT05124275. Target conditions include Presbyopia.
What happened to similar drugs?
1 of 6 similar drugs in Presbyopia were approved
Approved (1) Terminated (1) Active (5)
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehicleLENZ TherapeuticsPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05119920 | Phase 2 | Completed |
| NCT05124275 | Phase 2 | Completed |
Competing Products
14 competing products in Presbyopia